September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
6 citations
,
January 2012 in “Journal of Biomedicine and Biotechnology” Ustekinumab might work for severe psoriasis, but more research is needed to be sure.
4 citations
,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
3 citations
,
November 2023 in “Вопросы современной педиатрии” Ustekinumab effectively treated psoriasis and ulcerative colitis in a teen after infliximab caused complications.
May 2025 in “The Journal of Rheumatology” Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.
20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
March 2026 in “Frontiers in Medicine” New therapies for rare skin diseases show promise but need more research.
April 2016 in “Journal of The American Academy of Dermatology” Lichen planus may be associated with a higher risk of metabolic syndrome.
2 citations
,
February 2014 in “Journal of Crohn's and colitis” Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
February 2010 in “Journal of The American Academy of Dermatology” Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
January 2025 in “Dermatology Review” Acitretin may cause salivary gland inflammation.
Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.
15 citations
,
July 2010 in “Journal of Allergy and Clinical Immunology” A new cream, DHMEQ, reduces allergic skin inflammation effectively.
November 2024 in “Journal of Investigative Dermatology” Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.
Infliximab was effective in treating a scalp condition that did not respond to other treatments.
May 2022 in “Journal of Neurology Neurosurgery & Psychiatry” Erenumab significantly reduced migraine days or severity in most patients after 3 months.
278 citations
,
March 2013 in “Gut” Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.
144 citations
,
November 2020 in “Frontiers in immunology” Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.
101 citations
,
July 2020 in “Dermatologic therapy” COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.
59 citations
,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
49 citations
,
January 2018 in “Immunology” Psoriasis is linked to other autoimmune diseases and involves a specific inflammatory process.
36 citations
,
December 2015 in “Drugs” New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.
23 citations
,
July 2021 in “Advances in Therapy” Most people with Alopecia Areata don't get treatment within a year; it's costly and often comes with other health issues.
23 citations
,
November 2020 in “Central-European Journal of Immunology/Central European Journal of Immunology” Alopecia areata, a type of hair loss, is likely an autoimmune disease with a genetic link, but its exact cause is still unknown.
18 citations
,
September 2023 in “Nutrition Research Reviews” Higher fiber intake may reduce psoriasis severity, but more research is needed for effective dietary strategies.
16 citations
,
September 2020 in “British journal of dermatology/British journal of dermatology, Supplement” The article suggests that targeting specific immune pathways could help control and treat the skin disease hidradenitis suppurativa.
16 citations
,
May 2019 in “International Journal of Women's Dermatology” The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.
8 citations
,
May 2023 in “Cureus” Secukinumab for psoriasis may cause hair loss.
4 citations
,
January 2022 in “Current pharmaceutical design” Microsponges delivery system is a safe, versatile method for controlled drug release in various treatments.